cabergoline / Generic mfg. - LARVOL DELTA

MoonRISe-2, a Phase 2 Dose Expansion Within the Study of Erdafitinib Intravesical Drug Releasing System (TAR-210) for Localized Bladder Cancer: Study Design and Baseline Characteristics (AUA 2026) - P1/2 | "Funding: Johnson & Johnson.an = 53.bOther intravesical therapies included cabergoline, cretostimogene grenadenorepvec, and pirarubicin in 1 patient (1.9%) each.cn = 47.dn = 16.en = 7. Median sum of lesion size was 15 mm; 73.6% of patients had multiple (≥2) tumors. Majority of patients had multiple prior cancer-related procedures, including median of 2 TURBTs; 42.6% had prior IVES therapy, including BCG (18.5%), mitomycin C (13.0%), gemcitabine (11.1%), and epirubicin (3.7%) (Table)."

P2 data • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • FGFR

Precision Medicine in Prolactinomas: From Bench to Bedside. (PubMed, Mini Rev Med Chem) - "Dopamine agonists (DAs), particularly cabergoline, remain the standard first-line therapy; however, endoscopic surgery is increasingly used in selected patients (e.g., wellcircumscribed microadenomas and carefully chosen macroadenomas in experienced centers). For aggressive, DA-resistant, or malignant PRLomas, temozolomide remains the main systemic salvage option, and immunotherapy is being explored in early-phase settings. A precision approach will likely depend on integrating molecular stratification with clinical behavior to individualize treatment sequencing and improve long-term control and quality of life."

IO biomarker • Journal • Endocrine Disorders • Infertility • Oncology • Sexual Disorders • Solid Tumor

Prolactinoma assessment and management: an international multidisciplinary cross-sectional survey of current practice. (PubMed, Pituitary) - "International prolactinoma practice is heterogeneous and often discordant with contemporary guidance. Most notably, cabergoline therapy remains the preferred treatment strategy in microprolactinomas, and multidisciplinary discussion of prolactinoma cases is infrequent. This survey dataset serves as a roadmap for future research and clinical service improvement in prolactinoma care globally."

Journal • Fibrosis • Immunology • Neuroendocrine Tumor • Oncology • Pituitary Gland Carcinoma • Solid Tumor

Galactocele Rupture Causing Milk Contamination of a Prepectoral Implant Pocket: Diagnostic Pitfall and Implant Salvage. (PubMed, Plast Reconstr Surg Glob Open) - "Management included closure of the ductal communication, sequential antiseptic irrigation, drain placement, and lactation suppression with cabergoline...Galactocele rupture should be considered in the differential diagnosis of peri-implant fluid collections in postpartum patients with breast implants. Vigorous manipulation over a palpable mass should be avoided, and timely lactation suppression is critical for implant salvage regardless of closure integrity."

Journal • Infectious Disease

Massive Bilateral Breast Hypertrophy in Pregnancy Due to Gestational Gigantomastia: A Case Report and Review of the Literature. (PubMed, Cureus) - "Cabergoline was then administered to suppress lactation. In severe cases, surgical treatment (reduction mammoplasty or bilateral mastectomy with delayed reconstruction) is the mainstay of treatment, and bromocriptine is the best-established medical alternative, but with variable success. Coordinated multidisciplinary care is essential to optimise patient outcomes and minimise life-threatening complications."

Journal • Breast Cancer • Dermatology • Immunology • Infectious Disease • Inflammatory Breast Cancer • Musculoskeletal Pain • Oncology • Pain • Rare Diseases • Solid Tumor

Exploring the SPARAGMOS Study Protocol: review of a high-dose cabergoline interventional trial in microprolactinomas. (PubMed, Endocr Res) - P3 | "Under these conditions, the remission rate is expected to be low, around 30%. The findings from this trial have the potential to influence and redefine future therapeutic strategies for microprolactinoma."

Clinical • Journal • Oncology • Pituitary Gland Carcinoma

The Silent Valve Culprit: A Case Report and Literature Review of Isolated Cabergoline-Induced Mitral Regurgitation. (PubMed, Cureus) - "This case underscores the need to consider drug-induced valvular heart disease in the differential diagnosis, especially in regions where rheumatic etiology dominates the clinical landscape. Baseline and follow-up echocardiographic evaluations in patients receiving long-term cabergoline therapy are essential for early detection and prevention of irreversible valvular damage."

Journal • Cardiovascular • CNS Disorders • Congestive Heart Failure • Heart Failure • Movement Disorders • Parkinson's Disease

Severe Hypernatraemia Secondary to Adipsia Associated With a Pituitary Macroadenoma in a Dog: A Case Report. (PubMed, Vet Med Sci) - "This case expands the recognised neurological manifestations of pituitary-dependent hyperadrenocorticism and highlights pituitary macroadenoma as a potential cause of acquired adipsia and severe hypernatraemia in geriatric dogs."

Journal • Anorexia • Endocrine Disorders • Movement Disorders • Oncology • Otorhinolaryngology • Rare Diseases

Clinical features of MEN1 in children, adolescents, and young adults: a single-center study. (PubMed, Front Endocrinol (Lausanne)) - "Pituitary adenomas were detected in 52% (mostly non-functioning); one pediatric prolactinoma responded to cabergoline...PHPT represents the earliest and most prevalent manifestation and is frequently associated with renal and skeletal morbidity despite sometimes mild biochemical abnormalities. GEP-NETs and pituitary adenomas are also prevalent by late adolescence/young adulthood and are often indolent, suggesting structured, age-adapted multidisciplinary surveillance and early cascade genetic testing in at-risk families."

Journal • Retrospective data • Endocrine Disorders • Gastrointestinal Neuroendocrine Tumor • Hypoparathyroidism • Nephrology • Neuroendocrine Tumor • Oncology • Pancreatic Cancer • Pediatrics • Pituitary Gland Carcinoma • Renal Calculi • Solid Tumor

Concurrent human epidermal growth factor receptor 2-positive breast cancer with axillary nodal metastasis in a patient with pituitary prolactinoma: a case report. (PubMed, AME Case Rep) - "Adhering to a multidisciplinary plan while maintaining her cabergoline regimen uninterrupted, she received adjuvant chemotherapy, dual anti-HER2 blockade (trastuzumab and pertuzumab), and radiotherapy. She declined extended adjuvant neratinib due to gastrointestinal toxicity concerns...Furthermore, the paradoxical early lymphatic dissemination of a sub-centimeter primary tumor under physiological PRL levels suggests profound local crosstalk between HER2 and PRL receptor (PRLR) signaling. This necessitates vigilant management of even small, highly proliferative lesions in patients with concurrent endocrine comorbidities."

Journal • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Pain • Pituitary Gland Carcinoma • Solid Tumor • HER-2 • PRL • PRLR

Evaluation of endothelial dysfunction in women with prolactinoma. (PubMed, Pituitary) - "Patients with prolactinoma exhibit increased glucose intolerance and impaired endothelial function in the absence of overt global cardiac dysfunction. These alterations appear to be reversible following treatment."

Journal

Recurrent Pregnancy Loss: Novel Insights and Future Directions. (PubMed, J Obstet Gynaecol India) - "Management strategies include surgical correction of uterine anomalies, pharmacological interventions (levothyroxine, metformin, cabergoline, progesterone, low-dose aspirin, LMWH), and supportive care. Psychological support and multidisciplinary care are essential to improve outcomes. Despite advances, unexplained RPL remains prevalent, underscoring the need for precision medicine and integrative approaches to optimize reproductive success."

IO biomarker • Journal • Endocrine Disorders • Gene Therapies • Genetic Disorders • Hematological Disorders • Infectious Disease

A systematic review and meta-analysis on impulse-control disorders in patients with pituitary adenomas exposed to dopamine agonists. (PubMed, Front Endocrinol (Lausanne)) - "DAs were significantly associated with ICDs (random-effects models, OR, 95% CI: 2.39, 1.78-3.21; I2 = 0%, n=1247; p<0.01) regardless of age, sex, cabergoline dose, or treatment duration...Patients with pituitary adenomas treated with DAs showed a higher frequency of ICDs. Studies to confirm these findings and investigate the risk factors for ICDs in this patient population are warranted."

Clinical • Journal • Retrospective data • Review • CNS Disorders • Movement Disorders • Parkinson's Disease • Pituitary Gland Carcinoma

Successful Management of Postoperative Galactorrhea after Reduction Mammaplasty. (PubMed, Plast Reconstr Surg Glob Open) - "Endocrinology initiated cabergoline therapy, resulting in suppression of prolactin and resolution of the galactorrhea...Galactorrhea after breast reduction surgery secondary to transient hyperprolactinemia is a rare but clinically significant complication. Prompt recognition and multidisciplinary management including drain maintenance, lactation suppression, and exclusion of prolactinoma are important steps in preventing wound healing complications and achieving optimal outcomes."

Journal • Endocrine Disorders

Cardiometabolic effects of sequential prolactin states in dopamine agonist-treated prolactinoma patients: a retrospective longitudinal study. (PubMed, Pituitary) - "Normalization of prolactin concentrations was associated with significant improvements in body weight, BMI, and total cholesterol concentrations. In contrast, no significant cardiometabolic improvements were detected following the subsequent development of treatment-induced hypoprolactinemia. Furthermore, the magnitude of prolactin reduction was not independently associated with changes in anthropometric or metabolic parameters after multivariable adjustment. These findings suggest that the main cardiometabolic changes occur during the transition from hyperprolactinemia to normoprolactinemia. However, the specific cardiometabolic effects of treatment-induced hypoprolactinemia require confirmation in larger prospective studies."

Journal • Observational data • Retrospective data

Pituitary tumour shrinkage and diabetic remission in two cats with Cushing syndrome treated with cabergoline. (PubMed, J Small Anim Pract) - "Diabetes mellitus was initially managed with insulin glargine (Lantus; Sanofi-Aventis, Paris, France), nutritional therapy and continuous glucose monitoring...Endocrine testing revealed non-suppressible cortisol concentrations on low-dose-dexamethasone suppression test, elevated endogenous adenocorticotrophic hormone (ACTH) concentration and pituitary enlargement on computed tomography...Serial monitoring demonstrated a decrease in endogenous ACTH concentrations and a reduction in pituitary volume of 29% of baseline (Case 1) and of 52% of baseline (Case 2) after 8 months of treatment. These findings suggest that cabergoline may be a potential medical treatment option in cats with pituitary-dependent hypercortisolism."

Journal • Cardiovascular • Cushing’s Disease • Diabetes • Endocrine Disorders • Hypertension • Metabolic Disorders • Oncology • Pituitary Gland Carcinoma

Impact of endoscopy and related technologies on indications for transsphenoidal pituitary surgery for growth hormone-producing pituitary neuroendocrine tumors in McCune-Albright syndrome: illustrative case. (PubMed, J Neurosurg Case Lessons) - "Surgical treatment was previously considered difficult in cases of GH-producing pituitary tumor associated with MAS. However, recent advances in transnasal endoscopic surgery, including drilling and neuronavigation techniques, have made surgical endocrine remission achievable in some cases. Therefore, surgical indications should be reconsidered even in patients undergoing medical therapy. https://thejns.org/doi/10.3171/CASE26521."

Journal • Genetic Disorders • Neuroendocrine Tumor • Oncology • Otorhinolaryngology • Pituitary Gland Carcinoma • Solid Tumor • IGF1

PET-modulated fluorescence enhancement of cabergoline: A DFT and time-resolved fluorescence guided analytical strategy. (PubMed, Talanta) - "A comprehensive green chemistry assessment using AGREE metric, BAGI metric, ComplexMoGAPI, as well as RGB model, supported the method's outstanding green environmental profile and sustainable practical applicability. This PET-based fluorimetric strategy offers a simple, rapid, eco-friendly, and cost-effective alternative for the routine analysis of CG in quality control and bioanalytical laboratories."

Journal

Pituitary Apoplexy Without Chiasmal Compression Presenting With Radiographic Oculomotor Nerve Compression in a Prolactinoma: A Case Report. (PubMed, Cureus) - "We report the case of a 29-year-old Hispanic woman who presented to the emergency department (ED) with acute right-sided headache, dizziness, and transient blurry vision after the reinitiation of cabergoline therapy for a previously diagnosed prolactinoma...This case highlights an atypical presentation of pituitary apoplexy without classic chiasmal syndrome and emphasizes the importance of recognizing cavernous sinus cranial neuropathy as a potential presenting feature. Clinicians should maintain suspicion for pituitary apoplexy in patients with prolactinoma presenting with acute headache and cranial nerve (CN) abnormalities, even in the absence of visual field defects or optic pathway compression."

Journal • CNS Disorders • Endocrine Disorders • Hematological Disorders • Migraine • Nephrology • Ophthalmology • Pain • Pituitary Gland Carcinoma • Renal Disease • Women's Health

Restoration of spermatogenesis in a male with prolactinoma-induced hypogonadotropic hypogonadism using follitropin delta and recombinant choriogonadotropin alfa: a case report. (PubMed, J Assist Reprod Genet) - "This case provides the first evidence that follitropin delta can successfully replace conventional FSH preparations in male gonadotropin stimulation protocols. Spermatogenesis was restored within a favorable timeframe, enabling access to assisted reproductive technology (IVF/ICSI). Nevertheless, these findings are limited to a single case report and require confirmation in larger studies."

Journal • Endocrine Disorders • KEAP1

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Viaca (Sildenafil + Cabergoline) Compared With Sildenafil and Cabergoline (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Yanping Kong

New P1 trial • Erectile Dysfunction

Functioning pituitary adenomas in pregnancy: updates and controversies. (PubMed, Curr Opin Endocrinol Diabetes Obes) - "Owing to the relative rarity of functioning pituitary adenomas in pregnancy, current clinical practice and guidelines rely largely on limited retrospective evidence regarding the disease course and outcomes. Although new medical therapies for acromegaly and Cushing's disease are now available, data to support their use in pregnancy are lacking. Management therefore remains individualized and emphasizes shared decision-making."

Journal • Acromegaly • Cushing’s Disease • Endocrine Disorders • Pituitary Gland Carcinoma

When evidence transforms public policy: ending the criminalization of breastfeeding among women living with HIV in Chile (AIDS 2026) - "Subsequently, the health team filed a complaint with the family courts, requesting protective measures that included the separation of the mother and her daughter and the administration of cabergoline to inhibit lactation... The results are relevant to the lives and health of women living with HIV, demonstrating that decriminalizing breastfeeding reduces institutional and mental health harms without undermining the HIV response. Next steps focus on disseminating the documented experience to strengthen regulatory implementation and prevent further criminalization. The Chilean experience will be shared regionally with the Ministry of Health and with the support of organizations such as PAHO, with a view to replication in other countries."

Clinical • Human Immunodeficiency Virus • Infectious Disease

Increased impulsivity and higher odds of compulsive shopping among cabergoline-treated patients with prolactinoma: a case-control study. (PubMed, Pituitary) - "Patients with prolactinoma treated with cabergoline exhibit increased impulsivity, particularly in the attentional domain, along with higher odds of compulsive shopping. These results highlight the role of dopaminergic modulation and the influence of sociodemographic factors, supporting the importance of actively assessing impulsivity during clinical follow-up."

Journal

A rare case of bilateral axillary accessory breast tissue coexisting with prolactinoma in an adolescent girl. (PubMed, Turk J Pediatr) - "A 15-year-old girl with a diagnosed prolactinoma, receiving cabergoline treatment, presented with a week's history of tender, bilateral axillary masses...Accessory breast tissue may become more prominent during puberty or in hyperprolactinemic states, and it may be misdiagnosed. Recognizing this rare occurrence is key to avoiding unnecessary investigations or interventions."

Journal